Three lessons from making 100% in three months

When American banker J.P Morgan was asked what he thought stock prices would do next, he sat up in his chair and said: ‘They will fluctuate’. Acrux is the patent owner of a testosterone replacement therapy (TRT) called Axiron. When it gained regulatory approval from the US Food and Drug Administration (FDA) in 2010 its share price more than doubled from $1.80 to $4.40 over the following two years. But in January this year the FDA launched an investigation into the general safety of TRT. Acrux’s share price crashed back to 75 cents by June – it was trading at...

When American banker J.P Morgan was asked what he thought stock prices would do next, he sat up in his chair and said: ‘They will fluctuate’.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles